2019 is year of accumulation BTC,ETH Mid 2021 to end 2021 is for selling 2023 is year of accumulation BTC,ETH Mid 2025 to end 2025 is for selling 2027 is year of accumulation BTC,ETH Mid 2029 to end 2029 is for selling

I am excited to be an investor in trade(xyz) as they partner with ICE to bring 24/7 perpetual futures on Hyperliquid to the United States. As a market participant, I am looking forward to to using their innovative product to enhance my investment process.

The new bugbountyhunter site is *hopefully* going to be publicly released next month as I do some final touches, which means yes, zseano methodology v2 will be dropping before Christmas ;) So much work has gone into this and I hope to continue helping people on their bb journey!

If you look closely enough, breakthroughs in everything are accelerating exponentially. An exponential always starts off looking small.

Just two weeks after we released Gemini 4 Argon, introducing Carbon! Built on your feedback on Argon, Gemini 4 Carbon is SOTA for cyber capabilities, improves on coding usability & output quality, and ranks #1 on Artificial Analysis V5. We've also continued to invest in safety & security, with improved alignment and transparency. We're starting to roll out Carbon to a subset of cyber defenders through our Fairwind Program, and we’ll continue to iterate before expanding access!

Impressive

Back in Shenzhen after taking a high-speed train 1000km across the country and then flying back. It was so fast and easy and the infrastructure is amazing. Why can't we have nice things in North America too man 😭 (photos of Chongqing and Yangshuo and a spooky police robot)

We believe voice is the most natural way to interact with intelligence, so we created Dessa, the most authentic full-duplex speech model ever built. Talking with it feels like talking with a person…full of emotion, nuance, pauses, and a natural cadence. block.xyz/dessa

Objectively, the “Great Replacement” has already occurred

Sci-Fi company

Fun challenge, Vercel team is cool.

No more excuses. Everyone has a free hackbot now

ASML just gave TSMC full credit for driving the industry's 12" reticle enablement, making high-NA EUV cost-effective and ultimately useful for HVM. I feel bad for Intel here. They were pushing the big mask since day 1 and were the #1 cheerleader for high-NA while TSMC was dissing it. Of course you heard about this before TSMC even said anything about it, back in December of 2023 from @SemiAnalysis_. Shortly after, ASML dissed us in their earnings call, as just some bloggers who talk a lot. 🤣 newsletter.semianalysis.com/…

Outside rate-insensitive borrowing (public deficit, AI buildout), the most vulnerable sectors (housing) bear the full brunt of tightening.

Gemini 4 Argon is here. It’s available globally today for developers and enterprises in the paid tier of the Gemini API and the Gemini platform, for Ultra subscribers in Google Antigravity, and Ultra and Pro subscribers in the Gemini app and Search. Hope you all enjoy it!

Can we switch off diseases? siRNA drugs are, in my view and @JacobTref’s too, one of the most exciting developments in medicine. So we decided to do an episode! It’s a technology that can ‘silence’ harmful genes in the body. And there are lots of cases where you might want to silence genes: - Infectious diseases, where you can silence pathogen proteins or human proteins that pathogens depend on - Rare genetic diseases, where you can silence the production of mutated proteins - Cardiovascular diseases, by silencing proteins that raise cholesterol - Cancers, by silencing proteins that help tumour cells grow, survive, metabolize, metastasize, or resist treatment - and more! What’s even better is that siRNA drugs are: • Potentially tunable, meaning you could reduce the production of a protein, rather than silencing it entirely • Programmable, meaning you can quickly switch out which gene it targets by changing its sequence • Long-lasting: some drugs last for months, even half a year, with a single injection • Off-the-shelf: they typically don’t involve complicated surgeries or procedures, because of the way they’re delivered in the body Today, siRNA drugs are largely used to treat liver diseases, partly because that’s the easiest starting point. And they are extremely effective at it. One example is as a cholesterol drug: siRNAs can reduce PCSK9 levels by around 70%, reducing cholesterol levels by 50-60%, beyond the effect of statins. But we think it’s just a matter of time before they can be used to target other organs too. Will siRNA treat diseases of other organs? And what’s the catch? Listen to our latest episode of HARD DRUGS to find out! Chapters: 00:00 Introduction 09:58 siRNA trivia 28:14 The 20 year journey to make siRNA drugs 36:07 Which diseases could siRNA treat? 50:45 Programmable, long-lasting, scaleable drugs 54:32 The limits of siRNA 1:08:23 Conclusion

I talked about this back 6 years ago in my machine learning attack series. Back then I called it assume bias (LLMs weren't really that big of interest then) Now I just say Trust No AI embracethered.com/blog/posts…

For everyone wondering, so yeahh… that ₹7.71L payout = the $8,300 I earned from 3 valid Bugcrowd reports My first-ever bounty was $3K from Dell❤️ Still getting asked about the vulnerability, it’s not fully remediated yet..once it’s resolved, I’ll share the full details!!

There is no good reason for mosquitoes to exist in wealthy countries today. New technologies can get rid of the mosquito species that cause diseases like dengue, yellow fever, and malaria; and others can prevent them from carrying those diseases. worksinprogress.co/issue/mos… So why do mosquitoes still exist? In a new article for Works in Progress, Maya Rosen explains how state incapacity and risk aversion led to over a decade of delays and billions of unnecessary bites in the United States. Oxitec, for example, engineered an Aedes aegypti mosquito in such a way that its female offspring would die before adulthood. Through sustained releases, they showed they could reduce local mosquito populations by 80% or more, in field trials. They sought approval from the USDA in 2010, which then passed it to the FDA, which passed it to the EPA. In 2020, the EPA allowed them to conduct limited field trials in the Florida Keys. Two years ago, their experimental permit expired, and they still need another review before it can be used routinely. Their proposed field trial in California was withdrawn after public opposition. Another company, MosquitoMate, developed a technique involving Wolbachia, which also suppresses local mosquitoes. They then spent over fifteen years working through the system before finally receiving commercial registration nationwide in 2024. It seems that, sometimes, the barrier to getting rid of diseases isn’t technology at all. It’s policy and political will. New products shouldn’t get stuck in regulatory review for so long, especially if the delays are about basic questions like which agency has oversight over the product, rather than testing for safety. Though some of those uncertainties were being addressed, the broader changes haven’t materialized. After Biden’s 2022 executive order, the agencies planned to update how their coordinated framework was implemented. But Trump rescinded the order last year. Meanwhile, the EPA unit that reviews new mosquito control products is still a small office backlogged in reviewing a wide range of products. Mosquitoes are a policy choice. We can get rid of them. Will we choose to? worksinprogress.co/issue/mos…

Starship Flight 14 launched 26 Starlink V3 satellites into orbit today. SpaceX describes V3 as a ~2,000-kg satellite: 26 × ~2,000 kg = ~52,000 kg 60 V3 satellites per Starship launch would imply ~120 tonnes of satellites per launch. Starship at various COGS translates to: